The NeuroNEXT Network achieved an important milestone with the 
publication of the primary results from the first completed NeuroNEXT study, NN101 SMA, in the December 2017 issue of Annals of Neurology.
MediciNova, the industry sponsor of NN102 SPRINT-MS, announced the positive top-line results from the trial. The second funded NeuroNEXT trial, a study to evaluate the activity, safety, and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), has very promising results for MS treatment. Results indicate that Ibudilast demonstrated a statistically significant reduction in the rate of progression of whole brain atrophy as compared to placebo.
MediciNova announces the abstract from the NN102 SPRINT-MS study was selected as a platform presentation for late-breaking presentation at the 7th joint ECTRIMS-ACTRIMS meeting. Robert Fox will give the presentation of top line data on October 28, 2017 in Paris.
Chris Coffey and Laurie Gutmann presented at the 2014 NINDS-funded Clinical Trials Methodology Course.
View the poster presented at the 2013 Families of SMA Annual Meeting by the NN101 SMA team.
The August 2013 issue of Annals of Neurology describes how NeuroNEXT can streamline neurological research.
In a January/February 2013 editorial, the president of the Child Neurology Society praises the formation of the NeuroNEXT Network and the possibility for it to rapidly evaluate new treatments for neurological disorders.
View Steve Kolb's video announcement of the NN101 SMA study.
Article Summary: In February, 2012, the US National Institute for Neurological Disorders and Stroke (NINDS) is due to announce the first study to be supported by the National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). With this ambitious new network, NINDS aims to facilitate the progress of new drugs from the laboratory to the clinic, specifically at the stage of phase 2 trials and biomarker validation studies. New therapies for neurological diseases are undoubtedly needed, but how can NeuroNEXT make a difference?
Please visit the NIH page for information related to the NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) funding mechanism. The FOA is available for applications beginning January 5, 2018, through January 8, 2021.